Skip to main content
ODTX
NASDAQ Life Sciences

Odyssey Therapeutics Reports Positive Phase 2a Data for OD-001 in Ulcerative Colitis, Secures Funding into H2 2028

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$18.48
Mkt Cap
$871.778M
52W Low
$16
52W High
$18.72
52W Position info
16% above low
Off High info
1.3% below high
Rel. Volume info
1.4× avg
Market data snapshot near publication time

ODTX sits 16% above its 52-week low of $16.

Summary

Odyssey Therapeutics reported positive clinical proof-of-concept data for its lead candidate, OD-001, in a Phase 2a trial for moderate to severe ulcerative colitis, with 27% of patients achieving clinical remission. This significant update follows the company's recent IPO in May 2026. The company also announced a strong pro-forma cash position of $464.4 million, which is expected to fund operations into the second half of 2028. This positive clinical data de-risks the lead program and provides a clear path forward for a key asset. The substantial cash runway offers significant financial stability, allowing for continued pipeline advancement. Investors will watch for the initiation of Phase 2b and combination trials for OD-001 in the second half of 2026, with results expected in the second half of 2027.

At the time of this announcement, ODTX was trading at $18.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $871.8M. The 52-week trading range was $16.00 to $18.72. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

ODTX - Latest Insights

ODTX
Nov 04, 2026, 7:00 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $21.57
Real-time Price: $19.36 info
Change: -$2.21 (-10%) info
Market Cap: $930.594M info
ODTX
Nov 04, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $21.57
Real-time Price: $19.36 info
Change: -$2.21 (-10%) info
Market Cap: $930.594M info
ODTX
Oct 20, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $18.10
Real-time Price: $19.36 info
Change: +$1.26 (+7%) info
Market Cap: $930.594M info
ODTX
Oct 20, 2026, 7:00 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $17.80
Real-time Price: $19.36 info
Change: +$1.56 (+9%) info
Market Cap: $930.594M info
ODTX
Sep 08, 2026, 7:10 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $26.97
Real-time Price: $19.36 info
Change: -$7.61 (-28%) info
Market Cap: $930.594M info